| Heading: |
Mental Illness: Drugs |
| Question ID: |
1750767 |
| UIN: |
20768 |
| House: |
Commons |
| Date tabled: |
2024-12-17 |
| Asking Member ID: |
5288 |
| Asking Member display name: |
Dr Al Pinkerton
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Dr Al Pinkerton
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of(a) the utilisation of psilocybin-based treatments for mental health conditions and (b) commissioning further research into the therapeu |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-01-03 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
1506 |
| Answering Member display name: |
Andrew Gwynne
|
| Answering Member handle: |
GwynneMP
|
| Answering Member Twitter reference: |
@GwynneMP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Department recognises that the use of psychedelic-assisted psychotherapies, such as psilocybin, to treat mental illness is gaining attention both within the medical and scientific communities, as well as across the public more broadly. However, there ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |